Eurobio Scientific Financials
ALERS Stock | 25.60 0.05 0.19% |
Eurobio |
Understanding current and past Eurobio Scientific Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Eurobio Scientific's financial statements are interrelated, with each one affecting the others. For example, an increase in Eurobio Scientific's assets may result in an increase in income on the income statement.
Instrument | France Stock View All |
Exchange | Euronext Paris |
ISIN | FR0013240934 |
Business Address | 7 avenue de |
Sector | Healthcare |
Industry | Medical Devices |
Benchmark | Dow Jones Industrial |
Website | www.eurobio-scientific.com |
Phone | 33 1 69 79 64 80 |
You should never invest in Eurobio Scientific without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Eurobio Stock, because this is throwing your money away. Analyzing the key information contained in Eurobio Scientific's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Eurobio Scientific Key Financial Ratios
Eurobio Scientific's financial ratios allow both analysts and investors to convert raw data from Eurobio Scientific's financial statements into concise, actionable information that can be used to evaluate the performance of Eurobio Scientific over time and compare it to other companies across industries.Return On Equity | 0.45 | |||
Return On Asset | 0.23 | |||
Target Price | 32.0 | |||
Number Of Employees | 148 | |||
Beta | -0.0704 |
Eurobio Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eurobio Scientific's current stock value. Our valuation model uses many indicators to compare Eurobio Scientific value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eurobio Scientific competition to find correlations between indicators driving Eurobio Scientific's intrinsic value. More Info.Eurobio Scientific SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.51 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Eurobio Scientific SA is roughly 1.97 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Eurobio Scientific's earnings, one of the primary drivers of an investment's value.Eurobio Scientific Systematic Risk
Eurobio Scientific's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Eurobio Scientific volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Eurobio Scientific correlated with the market. If Beta is less than 0 Eurobio Scientific generally moves in the opposite direction as compared to the market. If Eurobio Scientific Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Eurobio Scientific is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Eurobio Scientific is generally in the same direction as the market. If Beta > 1 Eurobio Scientific moves generally in the same direction as, but more than the movement of the benchmark.
Eurobio Scientific November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Eurobio Scientific help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Eurobio Scientific SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Eurobio Scientific SA based on widely used predictive technical indicators. In general, we focus on analyzing Eurobio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Eurobio Scientific's daily price indicators and compare them against related drivers.
Downside Deviation | 0.5104 | |||
Information Ratio | (0.16) | |||
Maximum Drawdown | 3.15 | |||
Value At Risk | (0.40) | |||
Potential Upside | 0.7859 |
Additional Tools for Eurobio Stock Analysis
When running Eurobio Scientific's price analysis, check to measure Eurobio Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eurobio Scientific is operating at the current time. Most of Eurobio Scientific's value examination focuses on studying past and present price action to predict the probability of Eurobio Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eurobio Scientific's price. Additionally, you may evaluate how the addition of Eurobio Scientific to your portfolios can decrease your overall portfolio volatility.